Stephanie Yoon, M.D.

Radiation oncologist Stephanie Yoon, M.D., treats breast cancer along with brain and spine tumors because of the way cancer in those regions threatens the essence of what makes people who they are — their personalities, experiences, sensations and memories. Her career as a physician is an expression of her passion for helping people reach their highest potential and live their best lives, and she considers caring for people at such a vulnerable time a privilege.

Dr. Yoon offers multiple treatment strategies that deliver radiation precisely in order to maximize dosage to a tumor while sparing healthy tissue and minimizing side effects. These methods include magnetic resonance imaging-guided radiotherapy, stereotactic radiosurgery, stereotactic body radiotherapy, 3D image-guided radiotherapy and high-dose rate brachytherapy. She has authored more than a dozen peer-reviewed studies and gained expertise in the design of clinical trials.

Dedicated to improving diversity, equity and inclusion in medicine to best serve patients, Dr. Yoon served during her residency at University of California Los Angeles as executive chair for the Radiosurgery Society Resident Association and as an executive board member for the Society for Women in Radiation Oncology.

Professional Organizations

• 2021 – 2022, Executive Chair, The Radiosurgery Society
• 2020 – 2022, Executive Committee Membership Chair, Society for Women in Radiation Oncology
• 2019 – 2022, Education / Special Projects sub-committee member, Association of Residents in Radiation Oncology

Regional/Local

• 2019 – 2020, Member & Resident Representative, Radiological Society of North America
• 2019 – Present, Member, The Radiosurgery Society
• 2018 – Present, Member, Society for Women in Radiation Oncology
• 2018 – Present, Member, Los Angeles Radiological Society
• 2016 – Present, Member, American Society for Radiation Oncology
• 2022 – Present, Member, American Society for Clinical Oncology
• 2022 – Present, Member, American Radium Society

To view more publications, please visit Stephanie Yoon's NCBI link here.

• Corrales-Guerrero S, Cui T, Castro-Acetiuno V, Yang L, Nair S, Yoon S …Williams T. Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1. Cancer Lett. 2023, 21: 216308. DOI: 10.1016/j.canlet.2023.216308
• Chen B, Jin T, Ye N, Chen S, Rockne R, Yoon S … Salgia R. Differential distribution of brain metastases from non-small cell lung cancer based on mutation status. Brain Sciences. 2023, 13(7):1057. DOI: 10.3390/brainsci13071057
• Nikitas J, Smith L, Gao Y, Ma T, Sachdeva A, Yoon S…Kishan AU. Dosimetric implications of margin-reduced MRI-guided stereotactic body radiotherapy to the prostate bed following radical prostatectomy: post-hoc analysis of a phase II clinical trial. Radiotherapy Oncology. 2023; 183:109631. DOI: 10.1016/j.radonc.2023.109631
• Smith CP, Xiang M, Yoon S, Lee A, Ruan D… Mogahanki D. Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib. JTO Clin Res Rep. 2023, 3:100468. DOI: 10.1016/j.jtocrr.2023.100468
• Wu, T. C., Yoon, S. M., Cao, M., Raldow, A. C., & Xiang, M. Identifying predictors of on-table adaptation for pancreas stereotactic body radiotherapy (SBRT). Clinical and translational radiation oncology. 2023, 40, 100603. DOI: 10.1016/j.ctro.2023.100603
• Sonni I, Pra AD, O’Connell D, Benz M, Nguyen K, Yoon S …Calais J. PSMA PET/CT-based atlas for prostatic bed recurrence after radical prostatectomy: clinical implications for salvage radiation therapy. Journal of Nuclear Medicine. 2023. jnumed.122.265025. Advance online publication. DOI: 10.2967/jnumed.122.265025
• Ting MM, Ballas L, Wilhalme H, Sachdeva A, Chong S, Yoon S… et al. Quality-of-Life Outcomes and Toxicity Profile Among Patients with Localized Prostate Cancer after Radical Prostatectomy Treated with Stereotactic Body Radiotherapy: The SCIMITAR Multicenter Phase 2 Trial. International Journal of Radiation Oncology Biology and Physics. 2022, S0360-3016(22)03160-1. DOI: 10.1016/j.ijrobp.2022.08.041
• Pham J, Savjani R, Yoon S, Yang T, Gao Y …et al. Urethral Interfraciotnal Geometric and Dosimetric Variations of Prostate Cancer Patients: A Study Using Onboard MRI. Front Oncol. 2022. 12:916254. DOI: 10.3389/fonc.2022.916254
• Kundu P, Lin E, Yoon S, Parikh N, Ruan D…Chang AJ. Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients treated with Stereotactic Body Radiation Therapy with and without Hydrogel. Frontiers Oncology. 2022. DOI: 10.3389/fonc.2022.853246
• Zhou H, Cao M, Yoon S, Kishan A, Ruan D. Technical Note: Air bubble-induced performance degradation in automatic rectum segmentation from cone-beam CT. Med Phys. 2022; 1-5. DOI: 10.1002/mp.15443
• Zhou H, Cao M, Min Y, Yoon S, Kishan A, Ruan D. Ensemble learning and tensor regularization for cone-beam computed tomography-based pelvic organ segmentation. Med Phys. 2022; 00 1-13. DOI: 10.1002/mp.15475
• Gao Y, Pham J, Yoon S, Cao M, Hu P, Yang Y. Recent Advances in Functional MRI to Predict Treatment Response for Locally Advanced Rectal Cancer. Current Colorectal Cancer Reports. 2021. DOI: 10.1007/s11888-021-00470-x
• Yoon S, Luterstein E, Chu F, Cao M, Lamb J, Agazaryan N…Lee P. Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis. Cancer Med. 2021; 00:1-10. DOI: 10.1002/cam4.4139
• Yoon S, Suh R, Abtin, F, Moghanaki D, Genshaft S, Kamrava M…Chang AJ. Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation. Radiat Oncol. 2021; 16, 99. DOI: 10.1186/s13014-021-01826-1
• Cao M, Gao Y, Yoon S, Yang Y, Sheng K, Ballas L…Kishan AU. Interfractional geometric variations and dosimetric benefits of stereotactic MRI guided online adaptive radiotherapy (SMART) of prostate bed after radical prostatectomy: Post-hoc Analysis of a Phase II Trial. Cancers. 2021; 13, 2802. DOI: 10.3390/cancers13112802
• Valle LF, Chu FI, Kundu P, Yoon, S, Gilchrist T, Steinberg ML, Raldow A. National variation in the delivery of radiation oncology procedures in the non-facility-based setting. Cancer Medicine. 2021. DOI: 10.1002/cam4.4028
• Yoon S, Chu F, Ruan D, Steinberg ML, Raldow A, Lee, P. Assessment of Toxic Effects Associated with Dose-Fractionated Radiotherapy Among Patients with Cancer and Comorbid Collagen Vascular Disease. JAMA Network Open. 2021; 4(2):e2034074. DOI: 10.1001/jamanetworkopen.2020.34074
• Valle LF, Kundu P, Yoon S, Pennington D, Cao M, Lee P, Kishan A. (in press). Simulated consult and treatment exercise improve radiation oncology trainee confidence and knowledge. Journal of Education and Health Promotion.
• Valle LF, Chu F, Yoon S, Kundu P, Gilchrist T, Steinberg ML…Raldow A. Provider level variation in planning of radiation oncology procedures in the United States. Journal of Clinical Oncology- Oncology Practice. 2021. Jan; 8. DOI: 10.1200/OP.20.00441
• Gao Y, Yoon S, Savjani R, Pham J, Kalbasi A, Raldow A…Yang Y. Comparison and evaluation of distortion correction techniques on an MR-guided radiotherapy system. Medical Physics. 2021. Jan. DOI: 10.1002/mp.14634
• Yan R, Chu F, Gao Y, Yu V, Yoon S, Elashoff D…Yang Y. Time-resolved dosimetric analysis of cardiac substructures for radiotherapy of thoracic tumors using an MR-guided radiotherapy system. Physics and Imaging in Radiation Oncology. 2020, Dec. DOI: 10.1016/j.phro.2020.11.005
• Yoon S, Cao M, Aghdam N, Shabsovich D, Kahlon S, Ballas L, et al. Prostate bed and organ-at risk deformation: Prospective volumetric and dosimetric data from a phase II trial of stereotactic body radiotherapy after radical prostatectomy. Radiotherapy Oncology. 2020. Jul;148:44-50. DOI: 10.1016/j.radonc.2020.04.007
• Yoon S, Lee P, Raldow A. The evolving landscape of neoadjuvant radiation therapy for locally advanced rectal cancer. Current Colorectal Cancer Reports. 2020. Jun; 16:39-48. DOI: 10.1007/s11888-020-00451-6
• Rogers ZN, McFarland CD, Winter IP, Seoane JA, Brady JJ, Yoon S…Winslow M. Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. Nature Genetics. 2018 Apr; 50(4): 483-486. DOI: 10.1038/s41588-018-0083-2
• Yoon S, Shaik T, Hallman M. Therapeutic Management Options for Stage III Non-Small Cell Lung Cancer. World Journal of Clinical Oncology. 2017 Feb; 8 (1): 1-20. DOI: 10.5306/wjco.v8.i1.1
• Frumkin JP, Patra BN, Sevold A, Ganguly K, Patel C, Yoon S …Ray A. The interplay between chromosome stability and cell cycle control through gene-gene interaction and computational simulation. Nucleic Acids Research. 2016 Sep; 44(17): 8073-8085 DOI: 10.1093/nar/gkw715
• Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Yoon S … Jacks, T. Suppression of lung adenocarcinoma by Nkx2-1. Nature. 2011 May; 473(7345): 101-104. DOI: 10.1038/nature09881